Gemseki is a VC fund that invests in pharma & biotech companies and also facilitates global and regional licensing transactions.

• Signed and executed two in-licensing and investments in Orthopedics and Pain Management• Screened and evaluated licensing, collaborations, acquisition opportunities from a scientific, & commercial perspective in Cell & Gene Therapy, Regenerative medicine, Pain, Orthopedics & Anesthesiology• Evaluated products and/or companies by building financial models, performing due diligence, liaising internally to validate assumptions • Liaised with finance, supply, regulatory teams for post-transaction matters • Initiated and maintained relationship with top academic institutions for preclinical assets • Led the New Product Planning process for strategic decision on internal pipelines

• Signed and negotiated two out-licensing deals in area of pain management outside of the US to expand global footprint• Performed due diligence by leading cross-function teams on in-licensing deals in Pain Management, Gene & Cell Therapy, Anesthesiology

● Managed the relationship and post-acquisition negotiation with alliance partners for 9 global pharmaceutical & consumer health deals● Led all aspects of transaction operation for 8 acquisitions of Oncology, Anesthetic, Cardiology, Women’s health products, & OTC brands ● Led cross-functional team in Regulatory, Supply, Finance & Commercial team to ensure smooth transition ● Out-licensed products to drive 4-fold increase of sales in China, Korea and Japan● Grew brand revenue from $40 million to $400 million within 8 years

● Acquired Ceclor and Ilosone in the Philippines, adding 30% to bottom line● Managed all aspects of contract negotiation for Distributors for Product Acquisition● Created NPV model to make “go/no go” decision for affiliate set-up in Asia● Managed performance of partners and distributors in China, India, Korea, Indonesia, Singapore, Japan, Thailand and Asian countries to exceed sales targets and bottom line● Grew revenue by planning future portfolio of non-affiliates countries and sourcing generic and branded specialty products

• Identified new market trends and opportunities, assessed competitive landscape in solid tumors• Conducted pre-launch primary market research studies for positioning, messaging & sales aid development and post-launch performance tracking for melanoma and anti-fungal drugs• Track sales performance for Temodar and Intron A and identify growth potential in brain cancer and melanoma• Created market research plan & managed research budget• Conducted advisory board with KOL for clinical trial design of pipeline anti-emetics

• Built patient-based forecasting model to evaluate market potential and forecasted sales for Nexavar in renal cell cancer, hepatocellular cancer and melanoma• Improved long term profitability of Levitra by running R.O.I. studies • Forecasted scripts and predicted sales in oncology and men's health brands

• Helicopter view of Healthcare across Pharma, Biotech, Med Tech, Healthcare Services and Digital Health• Team-worked with general sales team to maximize penetration into key accounts• Initiated the global healthcare newsletter – for buy-side• Evaluated market potential by analyzing market data, pricing and inventory data• Improved ranking of the pharmaceutical team from #7 to #1 at the Global I.I. survey

• Built financial models, wrote the initial coverage report and forecasted revenues & earnings

• Product launches in CNS for Risperdal and Topamax in Hong Kong and China• Doubled sales of Risperdal within 6 months• Increased government drug expenditure on schizophrenia drugs through public relations program & negotiation